docetaxel + lapatinib + trastuzumab

This is a combination regimen consisting of three agents—docetaxel, lapatinib, and trastuzumab—used primarily in the treatment of HER2-positive breast cancer. Docetaxel is a taxane-class chemotherapeutic that inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis. Lapatinib is an oral small molecule tyrosine kinase inhibitor targeting both the human epidermal growth factor receptor 2 (HER2/ERBB2) and epidermal growth factor receptor (EGFR/ERBB1), blocking their intracellular phosphorylation domains. Trastuzumab is a monoclonal antibody that binds to the extracellular domain of HER2, inhibiting downstream signaling and mediating antibody-dependent cellular cytotoxicity. The triplet combination provides dual anti-HER2 blockade with chemotherapy, aiming for improved efficacy in neoadjuvant or metastatic settings compared to single-agent or doublet regimens[1][5]. This regimen has demonstrated higher pathological complete response rates but also increased toxicity.

Brand names

TaxotereHerceptinTykerbTyverb

Other names

lapatinib + docetaxel + trastuzumab